Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the former’s CART-ddBCMA, a late-stage product candidate. CART-ddBCMA, currently in phase 2 clinical development, is intended for the treatment of patients with relapsed or refractory multiple myeloma. Arcellx and Kite will share development, clinical trial, and commercialization costs […]